Safety and Tolerability Assessment of Intravenous QEQ278 in Patients with Advanced Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Renal Cell Carcinoma, and Head and Neck Squamous Cell Carcinoma

The primary objective of this study is to evaluate the **safety** and **tolerability** of intravenous QEQ278 in patients diagnosed with advanced solid tumors, specifically **non-small cell lung cancer**, **oesophageal squamous cell carcinoma**, **renal cell carcinoma**, and **squamous cell carcinoma of the head and neck**. Understanding the safety profile of QEQ278 is clinically relevant as it may inform treatment decisions and potential therapeutic applications for these malignancies.

The clinical trial involves a total of **37 participants** diagnosed with **non-small cell lung cancer**, oesophageal squamous cell carcinoma, renal cell carcinoma, or squamous cell carcinoma of the head and neck. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet or physical activity. The sponsor has not provided information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the **safety** and tolerability of intravenous QEQ278 in patients diagnosed with advanced solid tumors, specifically **non-small cell lung cancer**, **oesophageal squamous cell carcinoma**, **renal cell carcinoma**, and **squamous cell carcinoma of the head and neck**. This is a Phase 1 trial, characterized by a randomized, double-blind, and controlled design, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial is set to commence recruitment on February 1, 2023, and is expected to conclude by May 30, 2025, with the overall duration spanning approximately 28 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve comprehensive medical evaluations and baseline assessments. Following successful screening, participants will be enrolled and randomized into the study. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess the drug's safety profile, and collect data on any adverse events. These visits are crucial for evaluating the primary and secondary endpoints of the trial. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the treatment's effects.

The expected length of participant involvement in the trial is contingent upon the individual's response to the treatment and the absence of any adverse events that may necessitate early termination. Conditions that could lead to early withdrawal from the study include significant adverse reactions, non-compliance with study protocols, or the participant's decision to withdraw consent. The trial's design and procedures are meticulously structured to ensure the collection of robust and reliable data, contributing to the understanding of QEQ278's safety and tolerability in the specified patient population.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of February 1, 2023, and an estimated end date of May 30, 2025. The efficacy assessment will be conducted using predefined parameters or endpoints, although specific details regarding these endpoints are not provided. The trial will follow a systematic approach to measure, collect, and analyze efficacy data at designated timepoints throughout the study duration. The methods and tools for efficacy assessment are not specified, but they will adhere to standard clinical trial protocols to ensure accurate and reliable results. The trial's primary focus is to evaluate the safety and efficacy of the investigational product, with the ultimate goal of advancing medical knowledge and treatment options.